Development of a rapid zebrafish model for lead poisoning research and drugs screening

被引:1
|
作者
Guo S. [1 ,2 ]
Zhang X. [1 ]
Zhang Y. [2 ,3 ]
Chen X. [2 ]
Zhang Y. [2 ,3 ]
Cao B. [2 ]
Xia D. [1 ]
机构
[1] College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou
[2] Hunter Biotechnology, Inc., Hangzhou
[3] Schoool of Pharmacy, China Pharmaceutical University, Nanjing
关键词
Blood toxicity; Drug screening; Intermittent exposure; Lead; Neurotoxicity; Zebrafish model;
D O I
10.1016/j.chemosphere.2023.140561
中图分类号
学科分类号
摘要
Lead (Pb) contamination is a worldwide public health threaten. Besides close restraint of lead exposure, it's emergency to discover compounds that could help to cue toxicities caused by lead. Zebrafish embryos and early larvae can serve as valuable screening tools in early pre-clinical phase of drug screening and research. In order to establish a zebrafish lead poisoning model that could be used for drug screening and research, zebrafish embryos at 6 h post-fertilization (hpf) were treated with lead at different concentrations by soaking intermittently, raised in lead work solution at night while in fish water during the day. After treated for 90 h, death and severe trunk curvature were observed on zebrafish in 640 μM group, obvious dysplasia, blood toxicity, excessive reactive oxygen species (ROS), severe neurotoxicity, such as shorter length of peripheral motor neurons, neuronal apoptosis, and axonal injury, and neurobehavior impairment were induced by lead at 80, 160 and 320 μM, similar to phenotypes reported in rodent. Moreover, the mRNA level of genes related to neurodevelopment, memory, and antioxidation were significantly down regulated, and apoptosis-related genes were up regulated, consistent to zebrafish phenotypic change. Finally, zebrafish were intermittently exposed to 80 μM lead solution to establish the lead poisoning model, and the efficacy of a safe chelating agent Meso-2,3-Dimercaptosuccinic acid (DMSA) was tested at a series of concentrations to validate the zebrafish model. The result showed concentration-dependent decrease of lead content in zebrafish in DMSA treated groups compared with model group. The above data fully demonstrated a zebrafish model of lead poisoning suitable for drug screening was successfully developed, which was expected to provide a rapid and economic tools for discovering antidotes of lead and drugs of neuroprotection. © 2023 Elsevier Ltd
引用
收藏
相关论文
共 50 条
  • [21] Growing with the world: rapid development of the zebrafish research in China and the China Zebrafish Resource Center
    XunWei Xie
    LuYuan Pan
    YongHua Sun
    Science China Life Sciences, 2015, 58 : 396 - 399
  • [22] DIAGNOSTIC AND SCREENING PROCEDURES FOR LEAD POISONING
    LINFU, JS
    PEDIATRICS, 1971, 48 (03) : 488 - &
  • [23] SCREENING FOR LEAD-POISONING IN CHILDREN
    CHISOLM, JJ
    PEDIATRICS, 1973, 51 (02) : 280 - 283
  • [24] SCREENING STRATEGIES FOR LEAD-POISONING
    SCHAFFER, SJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (21): : 2555 - 2556
  • [25] SCREENING CHILDREN FOR LEAD-POISONING
    BAJOREK, MM
    WESTERN JOURNAL OF MEDICINE, 1995, 163 (01): : 64 - 64
  • [26] Behavioral screening for neuroactive drugs in zebrafish
    Rihel, Jason
    Schier, Alexander F.
    DEVELOPMENTAL NEUROBIOLOGY, 2012, 72 (03) : 373 - 385
  • [27] Screening for drugs to reduce aggression in zebrafish
    Norton, William H. J.
    NEUROPHARMACOLOGY, 2019, 156
  • [28] Rapid advances in research on and development of anticancer drugs in China
    Yao, Xu
    Du, Nan
    Hu, Shasha
    Wang, Lei
    Gao, Jianjun
    BIOSCIENCE TRENDS, 2019, 13 (05) : 461 - 463
  • [29] Lead poisoning after ingestion of ayurvedic drugs
    Schilling, U
    Mück, R
    Heidemann, E
    MEDIZINISCHE KLINIK, 2004, 99 (08) : 476 - 480
  • [30] Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing
    van Bree, Niek
    Oppelt, Ann-Sophie
    Lindstroem, Susanne
    Zhou, Leilei
    Boutin, Lola
    Coyle, Beth
    Swartling, Fredrik J.
    Johnsen, John Inge
    Braeutigam, Lars
    Wilhelm, Margareta
    NEURO-ONCOLOGY, 2024, 27 (03) : 779 - 794